Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Cara Therapeutics	Zymeworks	Endo International	Zealand Pharma A/S	PMV Pharmaceuticals
Symbol	NASDAQ:CARA	NYSE:ZYME	NASDAQ:ENDP	NASDAQ:ZEAL	NASDAQ:PMVP
Price Information
Current Price	$13.20	$28.59	$5.61	$29.00	$32.09
52 Week Range	Buy	Buy	Hold	Buy	Buy
MarketRank™
Overall Score	1.8	1.6	1.5	1.2	1.4
Analysis Score	3.5	3.4	3.0	3.5	2.4
Community Score	3.1	2.8	2.6	2.5	2.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	1.7	1.7	0.0	1.7
Earnings & Valuation Score	0.6	0.0	0.0	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Hold	Buy	Buy
Consensus Price Target	$32.00	$51.33	$7.67	$43.00	$38.00
% Upside from Price Target	142.42% upside	79.55% upside	36.66% upside	48.28% upside	18.42% upside
Trade Information
Market Cap	$660.69 million	$1.32 billion	$1.31 billion	$1.26 billion	$1.44 billion
Beta	1.7	0.75	1.41	1.19	N/A
Average Volume	1,051,990	524,068	3,819,250	11,822	163,194
Sales & Book Value
Annual Revenue	$19.89 million	$29.54 million	$2.91 billion	$6.20 million	N/A
Price / Sales	33.22	44.69	0.45	203.23	N/A
Cashflow	N/A	N/A	$4.07 per share	N/A	N/A
Price / Cash	N/A	N/A	1.38	N/A	N/A
Book Value	$4.66 per share	$6.21 per share	($3.82) per share	$5.85 per share	N/A
Price / Book	2.83	4.60	-1.47	4.96	N/A
Profitability
Net Income	$-106,370,000.00	$-145,440,000.00	$-422,640,000.00	$-85,670,000.00	N/A
EPS	($2.49)	($3.83)	$2.38	($2.54)	N/A
Trailing P/E Ratio	N/A	N/A	N/A	N/A	0.00
Forward P/E Ratio	N/A	N/A	2.44	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-360.35%	-569.13%	-5.30%	-214.31%	N/A
Return on Equity (ROE)	-64.36%	-44.06%	-85.80%	-38.34%	N/A
Return on Assets (ROA)	-53.22%	-34.36%	7.19%	-30.40%	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	N/A	N/A	N/A
Current Ratio	8.00%	6.48%	2.17%	6.76%	N/A
Quick Ratio	8.00%	6.48%	1.90%	6.51%	N/A
Ownership Information
Institutional Ownership Percentage	67.01%	75.11%	79.98%	4.32%	69.72%
Insider Ownership Percentage	5.70%	4.20%	1.50%	N/A	N/A
Miscellaneous
Employees	80	352	3,397	329	44
Shares Outstanding	50.05 million	46.17 million	233.31 million	43.45 million	44.93 million
Next Earnings Date	8/9/2021 (Estimated)	8/4/2021 (Estimated)	8/4/2021 (Estimated)	8/12/2021 (Estimated)	8/13/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Not Optionable	Not Optionable

Source	Headline
	PMV Pharmaceuticals (NASDAQ:PMVP) Shares Up 10.2% americanbankingnews.com - May 14 at 2:38 PM
	PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights finance.yahoo.com - May 14 at 1:00 PM
	PMV Pharmaceuticals (NASDAQ:PMVP) Sees Unusually-High Trading Volume americanbankingnews.com - May 13 at 11:54 AM
	PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Director Sells $63,742.29 in Stock americanbankingnews.com - May 12 at 9:36 PM
	Relative Strength Alert For PMV Pharmaceuticals nasdaq.com - May 12 at 1:40 PM
	PMV Pharmaceuticals (NASDAQ:PMVP) Hits New 1-Year Low at $27.00 americanbankingnews.com - May 12 at 10:58 AM
	PMV Pharmaceuticals (NASDAQ:PMVP) Stock Price Down 13.9% on Insider Selling americanbankingnews.com - May 11 at 11:30 AM
	Leila Alland Sells 4,000 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock americanbankingnews.com - May 10 at 6:20 PM
	PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) CFO Winston Kung Sells 4,500 Shares americanbankingnews.com - May 5 at 4:34 AM
	We're Interested To See How PMV Pharmaceuticals (NASDAQ:PMVP) Uses Its Cash Hoard To Grow nasdaq.com - May 2 at 2:24 PM
	PMV Pharmaceuticals (NASDAQ:PMVP) Trading Down 4.7% americanbankingnews.com - April 27 at 11:58 AM
	PMV Pharmaceuticals (NASDAQ:PMVP) Sees Strong Trading Volume americanbankingnews.com - April 22 at 11:59 AM
	PMV Pharmaceuticals (NASDAQ:PMVP) Shares Gap Up to $31.26 americanbankingnews.com - April 21 at 12:54 PM
	Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors benzinga.com - April 19 at 7:35 AM
	Pmv Pharmaceuticals Inc (PMVP) investing.com - April 12 at 12:40 AM
	PMV Pharma Presents Late-Breaking Preclinical... benzinga.com - April 10 at 6:16 PM
	PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the ... apnews.com - April 10 at 6:16 PM
	PMV Pharmaceuticals Inc. [PMVP] is -46.33% lower this YTD. Is it still time to buy? dbtnews.com - March 25 at 11:09 PM
	PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Down Almost -10.23% in 1 Month, But Long Term Looking Good marketingsentinel.com - March 25 at 1:07 PM
	PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American ... apnews.com - March 11 at 7:59 AM
	PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate ... apnews.com - March 4 at 3:38 AM
	PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights Nasdaq:PMVP compsmag.com - March 3 at 10:37 PM
	PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights finance.yahoo.com - March 3 at 5:35 PM
	PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board finance.yahoo.com - February 16 at 9:14 AM
	We're Not Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn finance.yahoo.com - December 25 at 3:10 PM

Date	Company	Brokerage	Action
5/5/2021	Cara Therapeutics	Needham & Company LLC	Lower Price Target
9/8/2020	Cara Therapeutics	Canaccord Genuity	Reiterated Rating
5/19/2020	Cara Therapeutics	Cantor Fitzgerald	Boost Price Target
4/21/2020	Cara Therapeutics	HC Wainwright	Boost Price Target
7/30/2019	Cara Therapeutics	Piper Jaffray Companies	Boost Price Target
5/29/2019	Cara Therapeutics	Laidlaw	Boost Price Target
2/6/2019	Cara Therapeutics	Jefferies Financial Group	Initiated Coverage
1/15/2019	Cara Therapeutics	Bank of America	Initiated Coverage
5/6/2021	Zymeworks	Raymond James	Set Price Target
3/30/2021	Zymeworks	Credit Suisse Group	Initiated Coverage
3/3/2021	Zymeworks	SVB Leerink	Reiterated Rating
1/29/2021	Zymeworks	Citigroup	Upgrade
1/28/2021	Zymeworks	Wells Fargo & Company	Lower Price Target
1/28/2021	Zymeworks	Barclays	Lower Price Target
9/29/2020	Zymeworks	JPMorgan Chase & Co.	Initiated Coverage
4/7/2021	Endo International	Royal Bank of Canada	Initiated Coverage
3/9/2021	Endo International	Morgan Stanley	Boost Price Target
1/4/2021	Endo International	Piper Sandler	Boost Price Target
7/27/2020	Endo International	The Goldman Sachs Group	Initiated Coverage
7/8/2020	Endo International	SunTrust Banks	Reiterated Rating
8/7/2019	Endo International	Mizuho	Reiterated Rating
9/19/2019	Zealand Pharma A/S	Guggenheim	Initiated Coverage
10/20/2020	PMV Pharmaceuticals	Evercore ISI	Initiated Coverage
10/20/2020	PMV Pharmaceuticals	Cowen	Initiated Coverage

(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources